Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma

Amit Sharma, Eun Joong Kim, Seokgyu Mun, Myung Sun Ji, Bong Geun Chung, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.

Original languageEnglish
Pages (from-to)628-633
Number of pages6
JournalDyes and Pigments
Publication statusPublished - 2019 Apr

Bibliographical note

Funding Information:
This work was supported by the National Research Foundation of Korea ( CRI 2018R1A3B1052702 , J.S.K; 2017R1D1A1B04033453 , E.J.K). This research was also supported by BioNano Health-Guard Research Center funded by the Ministry of Science and ICT(MSIT) of Korea as Global Frontier Project (Grant number H- GUARD_2013M3A6B2078950 ( 2014M3A6B2060302 )).

Publisher Copyright:
© 2018 Elsevier Ltd


  • Cancer
  • Drug delivery system
  • Hepatocellular carcinoma
  • Targeted therapy
  • Theranostic

ASJC Scopus subject areas

  • General Chemical Engineering
  • Process Chemistry and Technology


Dive into the research topics of 'Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this